



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## KWAR 23

Cat. No.:	HY-P99175
CAS No.:	2243227-60-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	<p>KWAR23 is an anti-human SIRP<math>\alpha</math> antibody. KWAR23 binds human SIRP<math>\alpha</math> with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research<sup>[1]</sup>.</p>									
<b>In Vitro</b>	<p>KWAR 23 (0-1 <math>\mu</math>M; 4 h) shows antitumor activity of human neutrophil and macrophage<sup>[1]</sup>.            KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.            Cell Viability Assay<sup>[1]</sup></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>Human macrophages and lymphoma cells</td> </tr> <tr> <td>Concentration:</td> <td>0-1 <math>\mu</math>M</td> </tr> <tr> <td>Incubation Time:</td> <td>4 h</td> </tr> <tr> <td>Result:</td> <td>Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.</td> </tr> </table>		Cell Line:	Human macrophages and lymphoma cells	Concentration:	0-1 $\mu$ M	Incubation Time:	4 h	Result:	Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.
Cell Line:	Human macrophages and lymphoma cells									
Concentration:	0-1 $\mu$ M									
Incubation Time:	4 h									
Result:	Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.									
<b>In Vivo</b>	<p>KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model<sup>[1]</sup>.            KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>SIRPA knock-in mouse model injected with Burkitt's lymphoma cells<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 10 mg/kg; every other day; 21 d</td> </tr> <tr> <td>Result:</td> <td>Led to strong inhibition of tumor growth when combined with Rituximab.</td> </tr> </table>		Animal Model:	SIRPA knock-in mouse model injected with Burkitt's lymphoma cells <sup>[1]</sup>	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d	Result:	Led to strong inhibition of tumor growth when combined with Rituximab.
Animal Model:	SIRPA knock-in mouse model injected with Burkitt's lymphoma cells <sup>[1]</sup>									
Dosage:	10 mg/kg									
Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d									
Result:	Led to strong inhibition of tumor growth when combined with Rituximab.									

### REFERENCES

---

[1]. Ring NG, et al. Anti-SIRP $\alpha$  antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA